ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1224 • ACR Convergence 2023

    Mental Health Screening Follow-Up in the Childhood-Onset Systemic Lupus Clinic

    Audrea Chen1, Tala El Tal2, Asha Jeyanathan1, Holly Convery1, Stephanie Wong1, Linda Hiraki1, Deborah Levy1 and Andrea Knight1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada

    Background/Purpose: Common barriers to conducting mental health (MH) screening in pediatric clinics include provider uncertainty with follow-up after screening, and concern with increasing burden of…
  • Abstract Number: 1261 • ACR Convergence 2023

    Network Analysis of Depression and Anxiety Symptoms in Chinese Rheumatoid Arthritis Patients

    Zhang Lijuan and Wu Beiwen, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Background/Purpose: Rheumatoid arthritis (RA) patients are susceptible to comorbid anxiety and depression. From the network model perspective, comorbidity is due to direct interactions between depression…
  • Abstract Number: 1267 • ACR Convergence 2023

    Lower Herpes Zoster Rate of Tocilizumab and Tofacitinib in Patients Undergoing Treatment for Rheumatoid Arthritis

    Yao fan Fang1, Lai-Chu See2 and Shu-Hao Chang2, 1Chang-Gung Memorial Hospital – Linkou, Taoyuan, Taiwan, 2Biostatistics Core Laboratory, Molecular Medicine Research centre, Chang Gung University, Taoyuan City, Taiwan

    Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) have become the primary treatment option for rheumatoid arthritis (RA) from 2010 in Taiwan. Tocilizumab is an interleukin-6 receptor…
  • Abstract Number: 1264 • ACR Convergence 2023

    Nomination of Biomarkers for Self-testing Disease Activity in Rheumatoid Arthritis Using Patient Similarity Networks: A Pilot Study

    Martina Skacelova1, Ondrej Janca2, Milos Kudelka2, Bishu Shrestha3, Pavel Horak4 and Eva Kriegova3, 1Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic, 2Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic, 3Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic, Olomouc, Czech Republic, 4Department of Internal Medicine III- Nephrology, Rheumatology, Endocrinology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic

    Background/Purpose: Although telemedicine in rheumatoid arthritis (RA) could improve disease control with lower healthcare costs, knowledge of suitable parameters for self-testing disease activity still remains…
  • Abstract Number: 1218 • ACR Convergence 2023

    Discovering the Potential Application of Digital Biomarkers for Inflammatory Arthritis Patients, a Design Thinking Approach; Preliminary Results of the Patients’ Perspective

    patty de Groot1, ilja Tchetverikov2, Yvonne P. M. Goekoop-Ruiterman3, Wendy Olsder4, Rien Bakker5, Marc r. Kok6, Jasper Foolen7 and Jolanda J. Luime1, 1Erasmus Medical Center, Rotterdam, Netherlands, 2Albert Sweitzer Hospital, Dordrecht, Netherlands, 3Haga Ziekenhuis, The Hague, Netherlands, 4Erasmus School of Health Policy and Management, Rotterdam, Netherlands, 5Consortium Beroepsonderwijs, Information Communication Technology, Amersfoort, Netherlands, 6Maasstad Hospital, Rotterdam, Netherlands, 7Eindhoven University of Technology deparment of Biomedical Engineering, Eindhoven, Netherlands

    Background/Purpose: The Inflammatory Arthritis (IA) patient population is growing, whilst facing a shortage of health care professionals (HCPs). It is impossible to meet the future…
  • Abstract Number: 1255 • ACR Convergence 2023

    Clinical Characteristics and Disease Outcomes of anti-NXP2 Positive Juvenile Dermatomyositis: A Single Center Cohort

    Sarah Molina1, Dawn Gist2, Marietta De Guzman3, Eyal Muscal4, Jamie Lai2 and Maria Pereira3, 1Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, 2Baylor College of Medicine / Texas Children's Hospital, Houston, TX, 3Baylor College of Medicine, Houston, TX, 4Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory myopathy with clinically heterogeneous presentations that can be categorized by myositis-specific antibodies (MSAs). NXP2 is among…
  • Abstract Number: 1258 • ACR Convergence 2023

    “What Is My Risk Really?”: A Qualitative Exploration and Ideal-Type Analysis of Preventive Interventions Among Individuals at Risk of Rheumatoid Arthritis

    Lara S Chapman1, Heidi J Siddle1, Stefan Serban2, Kulveer Mankia1, Christopher Rooney3, Zhain Mustufvi4, Simon Pini5 and Karen Vinall-Collier4, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Public Health Directorate, NHS England North West Region, Manchester, United Kingdom, 3University of Leeds, Leeds, United Kingdom, 4School of Dentistry, University of Leeds, Leeds, United Kingdom, 5Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom

    Background/Purpose: A preclinical phase of rheumatoid arthritis (RA), in which ‘at-risk’ individuals develop autoantibodies and/or symptoms and progress to clinical arthritis and classifiable RA, is…
  • Abstract Number: 1270 • ACR Convergence 2023

    Identification of Subclinical Atherosclerosis by Six Cardiovascular Risk Calculators in Rheumatoid Arthritis Patients

    Natalia Guajardo-Jauregui1, José Ramón Azpiri-López2, Dionicio A. Galarza-Delgado2, Iris Colunga2, Jesus Alberto Cardenas-De la Garza3 and Rosa Arvizu-Rivera4, 1Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, 4Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico

    Background/Purpose: Current EULAR recommendations for cardiovascular risk (CVR) assessment in rheumatoid arthritis (RA) patients indicate that the CVR evaluation should be performed according to national…
  • Abstract Number: 1271 • ACR Convergence 2023

    Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)

    Bong-Ki Hong1, Sungyong You2, Naeun Lee1, Jung Gon Kim3, Kijun Lee4, Ji Hyeon Ju5, Wan-Uk Kim1 and Ho-Youn Kim6, 1The Catholic University of Korea, Seoul, South Korea, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3Inje University Ilsan Paik Hospital, Goyang, South Korea, 4YiPSCELL, Secho, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 6HoYoun Kim's Clinic for Arthritis Rheumatism, Seoul, South Korea

    Background/Purpose: Recent research has revealed a significant upregulation of IFNγ-related genes in RA patients, though the underlying mechanisms and implications are still unclear. To further…
  • Abstract Number: 1257 • ACR Convergence 2023

    The Psychological Experience of Work for People with Inflammatory Arthritis (IA)

    Joan Westreich1, Adena Batterman1, Anna Balakrishnan1, Roberta Horton1, Minerva Nong1, Vivian Bykerk2 and Theodore Fields1, 1Hospital for Special Surgery, New York, NY, 2Department of Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose: A large body of research reports that people with inflammatory arthritis (IA) are at increased risk for work disability, which profoundly affects all aspects…
  • Abstract Number: 1226 • ACR Convergence 2023

    Examining the Relationship Between Socioenvironmental Factors and Cognitive Functioning in Youth with Childhood-Onset Systemic Lupus Erythematosus

    Ashley Danguecan1, Ibrahim Mohamed2, Sarah Mossad1, Tala El Tal3, Adrienne Davis1, Asha Jeyanathan1, Sona Sandhu1, Lawrence Ng1, Paris Moaf1, Deborah Levy1, Linda Hiraki1 and Andrea Knight1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2The Hospital for Sick Children, Brampton, ON, Canada, 3Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada

    Background/Purpose: Problems with cognitive functioning are common in childhood-onset systemic lupus erythematosus (cSLE); these may be attributed to many factors including underlying brain inflammation. Socioenvironmental…
  • Abstract Number: 1262 • ACR Convergence 2023

    “Somebody Who’s Been There and Can Understand the Challenges That You’re Going Through”: Participant Perspectives of a Resilience-Based Energy Management Online Intervention for Systemic Sclerosis with Peer Health Coaches

    Yen Chen1, Alexandra Harper2, Tiffany Phanhdone3, Mary Alore1, Sheri Hicks1, Adam Pape1, Gina Jay1, Shannen Bolde1, Jennie Feldpausch1, Dinesh Khanna1 and Susan Murphy4, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ypsilanti Charter Twp, MI, 3Northwestern University, Chicago, IL, 4University of Michigan, Plymouth, MI

    Background/Purpose: People with systemic sclerosis (SSc) often experience fatigue, which impacts daily life functioning and quality of life. We developed a 12-week, resilience-based energy management…
  • Abstract Number: 1228 • ACR Convergence 2023

    Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach

    Caterina Matucci-Cerinic1, helene Palluy2, Sulaiman Al-Mayouf3, Paul Brogan4, Luca Cantarini5, Ahmet Gul6, Ozgur Kasapcopur7, Jasmin B. Kuemmerle-Deschner8, Seza Ozen9, david saadoun10, Farhad Shahram11, Francesca Bovis12, Eugenia mosci13, Nicolino Ruperto14, Marco Gattorno15 and Isabelle Kone-Paut16, 1DINOGMI, University of Genoa; IRCCS Istituto Giannina Gaslini, UOC Rheumatology and autoinflammatory diseases, Genova, Italy, 2Pediatric rheumatology and CEREMAIA, Bicêtre hospital, APHP, University of Paris Saclay, Paris, France, 3King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, 4UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 5Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy, 6Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 7Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, 8med.uni-tuebingen, Tübingen, Germany, 9Hacettepe University Medical Faculty, Ankara, Turkey, 10Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Inflammatoires et de l’Amylose inflammatoire, F-75013, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière., Neuilly sur Seine, France, 11Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran, 12Dept of Health Sciences (DISSAL), University of Genoa, Genova, Italy, 13UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, IRCCS Istituto Giannina Gaslini, Genova, Italy, 14IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, 15UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, 16Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France

    Background/Purpose: Behçet's disease (BD) is an autoinflammatory disease characterized by a variable vessel vasculitis. In the past, several criteria have been created for adult BD…
  • Abstract Number: 1243 • ACR Convergence 2023

    Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study

    Ryan Mitacek, Qiong Liu, Linda Wagner-Weiner, Shireen Hashmat and Anthony Chang, University of Chicago, Chicago, IL

    Background/Purpose: Lupus nephritis (LN) is associated with significant morbidity and mortality. The 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria and the NIH…
  • Abstract Number: 1227 • ACR Convergence 2023

    Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus

    Jordan Roberts1, Anna Faino2, Mersine Bryan1, Jonathan Cogen1 and Esi Morgan1, 1Seattle Children's Hospital, Seattle, WA, 2Seattle Children’s Research Institute, Seattle, WA

    Background/Purpose: Rituximab has been associated with high rates of infection among adults with systemic lupus erythematosus. However, studies of infection risk following rituximab among children…
  • « Previous Page
  • 1
  • …
  • 378
  • 379
  • 380
  • 381
  • 382
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology